|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM108858510 |
| 003 |
DE-627 |
| 005 |
20231222150109.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0363.xml
|
| 035 |
|
|
|a (DE-627)NLM108858510
|
| 035 |
|
|
|a (NLM)10964539
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Soulika, A M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.09.2000
|
| 500 |
|
|
|a Date Revised 14.11.2007
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2000 Academic Press.
|
| 520 |
|
|
|a Complement activation products are major components of the inflammatory response induced by cardiac surgery and cardiopulmonary bypass which contribute to postoperative organ dysfunction, fluid accumulation, and morbidity. Activation of the complement system occurs during extracorporeal circulation, during reperfusion of ischemic tissue, and after the formation of heparin-protamine complexes. In this study we examine the efficacy of Compstatin, a recently discovered peptide inhibitor of complement, in preventing heparin/protamine-induced complement activation in baboons. The study was performed in baboons because Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans); Compstatin inhibits only the activation of primates' complement system. After testing various doses and administration regimens, Compstatin produced complete inhibition at a total dose of 21 mg/kg when given as a combination of bolus injection and infusion. Compstatin completely inhibited in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures. This study indicates that Compstatin is a safe and effective complement inhibitor that has the potential to prevent complement activation during and after clinical cardiac surgery. Furthermore, Compstatin can serve as the prototype for designing an orally administrated drug
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Complement Inactivator Proteins
|2 NLM
|
| 650 |
|
7 |
|a Hemoglobins
|2 NLM
|
| 650 |
|
7 |
|a Peptides, Cyclic
|2 NLM
|
| 650 |
|
7 |
|a Protamines
|2 NLM
|
| 650 |
|
7 |
|a compstatin
|2 NLM
|
| 650 |
|
7 |
|a protamine heparin aggregate
|2 NLM
|
| 650 |
|
7 |
|a Heparin
|2 NLM
|
| 650 |
|
7 |
|a 9005-49-6
|2 NLM
|
| 700 |
1 |
|
|a Khan, M M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hattori, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bowen, F W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Richardson, B A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hack, C E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sahu, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Edmunds, L H
|c Jr
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lambris, J D
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 96(2000), 3 vom: 01. Sept., Seite 212-21
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:96
|g year:2000
|g number:3
|g day:01
|g month:09
|g pages:212-21
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 96
|j 2000
|e 3
|b 01
|c 09
|h 212-21
|